Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article contrasts HeartFlow (HTFL) and Iovance (IOVA) on risk-adjusted 2026 outlooks, citing FY2025 revenue of ~$176M (+40% y/y) for HeartFlow but a net loss of $116.8M, versus Iovance revenue of $263.5M (+60.6% y/y) but a larger net loss of ~$391M. Both companies show low leverage (debt-to-equity ~0.1x), yet cash burn is material—HeartFlow FCF of about -$59.0M and Iovance FCF of about -$336.2M—while HeartFlow faces DOJ scrutiny and proposed 2026 Medicare rules implying a 15% reimbursement reduction to its core service. Netting out growth with concentrated revenue and ongoing cash burn (and Iovance’s $2.9B accumulated deficit), the piece leans cautiously toward Iovance as the better risk-adjusted buy mainly on a lower P/S ratio (5.3x vs 13.8x).

Analysis

The market should view HTFL less as an AI compounder and more as a reimbursement-sensitive consumable. When one product drives nearly all revenue, a policy haircut flows directly into growth deceleration and multiple compression, while the DOJ overhang adds a second discount rate because it raises the odds of channel disruption or tighter provider economics. That makes GEHC and PHG the cleaner relative beneficiaries if hospitals standardize on broader imaging platforms rather than a niche workflow point solution.

IOVA is the higher-beta execution story: the near-term question is not demand, but whether manufacturing and cash burn can keep pace with adoption. If quarterly growth stays above 20% and gross margins stabilize, the stock can re-rate as a commercial platform; if not, dilution risk becomes the dominant factor over the next 2-4 quarters. The balance sheet is not levered, but the equity still behaves like a financing instrument until runway visibility improves.

Contrarian view: the consensus may be underpricing how asymmetric the policy risk is for HTFL and over-penalizing IOVA for burn if sales momentum persists. The cleanest setup is relative value, not an outright long in either name. The thesis would be falsified by an unchanged Medicare rule for HTFL or by IOVA missing sequential revenue growth and issuing equity before year-end.

Key Decisions for Investors

• Prefer a relative-value short HTFL / long GEHC pair on any post-commentary strength; the trade benefits if reimbursement pressure pushes volume toward broader installed-base competitors over the next 1-3 months.
• Buy HTFL put spreads or short HTFL into rallies ahead of Medicare rule finalization or any DOJ headline; risk/reward is favorable because policy clarity can reprice the stock quickly, while upside requires both clean regulation and faster commercialization.
• Hold IOVA only as a catalyst-driven position into quarterly prints; add only if sequential revenue growth stays >20% and cash burn does not worsen, otherwise avoid because dilution risk can overwhelm operating progress over 2-4 quarters.
• Watch CLLS and NVS as second-order winners only if IOVA demonstrates durable scale; do not chase them today since milestone/royalty optionality is too indirect for a near-term trade.